ROCKET PHARMACEUTICALS INC (RCKT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RCKT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RCKT | Director | 65 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PTCT | President, Chief Executive Officer and Director | 65 | ["President, Chief Executive Officer and Director of Volastra Therapeutics.","Former Chief Executive Officer of TScan Therapeutics, Inc.","Former President and Chief Executive Officer of Inotek Pharmaceuticals, Inc.","Former Executive Vice President and Chief Financial Officer of Human Genome Sciences, Inc.","Former Executive Vice President and Chief Financial Officer of Sepracor, Inc.","Experience in investment banking with Lehman Brothers Inc.","extensive executive leadership experience","knowledge of our industry","B.A. from Rice University","M.B.A. from the Tuck School of Business at Dartmouth College"] | ["Audit Committee","Compensation Committee"] | 2026 |
Biography sourced from the proxy statement filing.
David P. Southwell has served as one of our directors since August 2014. He served as President, Chief Executive Officer and board member of TScan Therapeutics, a publicly-traded, clinical-stage biopharmaceutical company from October 2018 through March 2023. Mr. Southwell previously served as the President and Chief Executive Officer of Inotek from July 2014 to January 2018. From March 2010 to October 2012, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc., which is owned by GlaxoSmithKline plc. Prior to his time at Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to July 2008. Mr. Southwell has also served on the board of directors of PTC Therapeutics Inc. since December 2005 and Spero Therapeutics, Inc. from February 2018 to April 2019. Mr. Southwell received a B.A. from Rice University and an M.B.A. from Dartmouth College, where he served on the Board of Overseers from 2011 to 2020. We believe that Mr. Southwell s qualifications to serve on our Board include his broad experience serving on the boards of directors of public companies, his specific experience with public therapeutics companies and his executive leadership, managerial and business experience.